Free Trial
NASDAQ:KMDA

Kamada (KMDA) Stock Price, News & Analysis

$5.82
0.00 (0.00%)
(As of 07/17/2024 ET)
Today's Range
$5.74
$5.82
50-Day Range
$4.78
$6.25
52-Week Range
$4.08
$6.53
Volume
32,268 shs
Average Volume
24,642 shs
Market Capitalization
$334.53 million
P/E Ratio
25.31
Dividend Yield
N/A
Price Target
$14.50

Kamada MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
149.1% Upside
$14.50 Price Target
Short Interest
Healthy
0.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.01mentions of Kamada in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
33.33%
From $0.24 to $0.32 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.27 out of 5 stars

Medical Sector

143rd out of 914 stocks

Pharmaceutical Preparations Industry

58th out of 433 stocks

KMDA stock logo

About Kamada Stock (NASDAQ:KMDA)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

KMDA Stock Price History

KMDA Stock News Headlines

StockNews.com Initiates Coverage on Kamada (NASDAQ:KMDA)
I’m giving you the name of this investment for free
I want to help you achieve that right by accessing a new business model in America that has been unlocked by a billionaire who may end up sitting in Trump’s cabinet.
3 Pharma Stocks With May Potential
I’m giving you the name of this investment for free
I want to help you achieve that right by accessing a new business model in America that has been unlocked by a billionaire who may end up sitting in Trump’s cabinet.
Kamada earnings: here's what Wall Street expects
KMDA Aug 2024 10.000 call
KMDA May 2024 5.000 call
KMDA Apr 2024 10.000 call
Preview: Kamada's Earnings
See More Headlines
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/17/2024
Next Earnings (Estimated)
8/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KMDA
Employees
378
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.50
High Stock Price Target
$18.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+151.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$8.28 million
Pretax Margin
8.47%

Debt

Sales & Book Value

Annual Sales
$142.52 million
Cash Flow
$0.43 per share
Book Value
$4.25 per share

Miscellaneous

Free Float
36,730,000
Market Cap
$331.66 million
Optionable
Optionable
Beta
1.06
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Amir London (Age 55)
    Chief Executive Officer
    Comp: $611k
  • Mr. Chaime Orlev (Age 54)
    Chief Financial Officer
    Comp: $387k
  • Mr. Eran Nir (Age 51)
    Chief Operating Officer
    Comp: $332k
  • Mr. Jon R. Knight (Age 58)
    Vice President of US Commercial Operations
    Comp: $307k
  • Mr. Boris Gorelik (Age 43)
    Vice President of Business Development & Strategic Programs
    Comp: $410k
  • Mr. David Tsur (Age 74)
    Co-Founder & Independent Deputy Chairman of the Board
    Comp: $252k
  • Mr. Nir Livneh B.A. (Age 44)
    L.L.B., VP, General Counsel & Corporate Secretary
  • Ms. Hanni Neheman (Age 54)
    Vice President of Marketing & Sales
  • Ms. Liron Reshef (Age 52)
    Vice President of Human Resources
  • Ms. Shavit Beladev
    Vice President of Kamada Plasma

KMDA Stock Analysis - Frequently Asked Questions

How have KMDA shares performed this year?

Kamada's stock was trading at $6.12 at the beginning of the year. Since then, KMDA stock has decreased by 4.9% and is now trading at $5.82.
View the best growth stocks for 2024 here
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) announced its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.02. The biotechnology company had revenue of $37.74 million for the quarter, compared to analyst estimates of $38.01 million. Kamada had a net margin of 8.33% and a trailing twelve-month return on equity of 5.50%.

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN) and NIC (EGOV).

This page (NASDAQ:KMDA) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners